Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 114

Sort by

Sort Order Select

Journal Articles

Safety and effectiveness of brentuximab vedotin in Chinese adult patients with classical Hodgkin's lymphoma: Results from a multicenter, prospective, observational, real-world study

Wei Li, Chuanxu Liu, Wenyang Huang, Ou Bai, Lihong Liu, Zengjun Li, Wei Xu, Wei Zhang, Liping Su, Kaiyang Ding, Luqun Wang, Guohui Cui, Hongmei Jing, Jianli Wang, Ziheng Guo, Weili Zhao, Huilai Zhang

Blood (2025) 146 (Supplement 1): 7135.

https://doi.org/10.1182/blood-2025-7135

Published: 2025

Journal Articles

Clinical activity and immune correlates of glofitamab combined with tislelizumab in relapsed/refractory follicular lymphoma: A translational study

Zhao Peiqi, Lanfang Li, Zhengzi Qian, Wei Li, Shiyong Zhou, Lihua Qiu, Xianming Liu, Huilai Zhang

Blood (2025) 146 (Supplement 1): 3595.

https://doi.org/10.1182/blood-2025-3595

Published: 2025

Journal Articles

Final analysis of the randomized phase 2 ROSEWOOD study of zanubrutinib + obinutuzumab vs obinutuzumab monotherapy in patients with relapsed/refractory follicular lymphoma

Pier Luigi Zinzani, Jiri Mayer, Christopher Flowers, Fontanet Bijou, Ana C. De Oliveira, Yuqin Song, Qing-Yuan Zhang, Marco Brociner, Krimo Bouabdallah, Peter S. Ganly, Huilai Zhang, Sam Yuen, Marek Trneny, Rebecca Auer, Sha Huang, Jiayi Shen, Jamie Hirata, Judith Trotman

Blood (2025) 146 (Supplement 1): 227.

https://doi.org/10.1182/blood-2025-227

Published: 2025

Journal Articles

Proteolysis-targeting chimera (PROTAC) targeting bruton tyrosine kinase (BTK) degradation for cancer therapy in mantle cell lymphoma

Xiaohui Wang, Xianhuo Wang, Huilai Zhang

Blood (2025) 146 (Supplement 1): 7852.

https://doi.org/10.1182/blood-2025-7852

Published: 2025

Journal Articles

Frontline brentuximab vedotin and PD-1 inhibitors in elderly Chinese Hodgkin lymphoma: Real-world survival benefits validated by geriatric and biomarker correlates

Blood (2025) 146 (Supplement 1): 1843.

https://doi.org/10.1182/blood-2025-1843

Published: 2025

Journal Articles

Sustained clinical benefit of glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab plus GemOx (R-GemOx) in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): 3-year follow-up of STARGLO

Blood (2025) 146 (Supplement 1): 5519.

https://doi.org/10.1182/blood-2025-5519

Published: 2025

Journal Articles

Improvements in health-related quality of life (HRQoL) in the SUNMO study: Subcutaneous (SC) mosunetuzumab plus polatuzumab vedotin (Mosun-Pola) vs rituximab, gemcitabine and oxaliplatin (R-GemOx) in patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) after at least one prior therapy

Elizabeth Budde, Jason Westin, Huilai Zhang, Dai Maruyama, Eduardo M. Rego, Huangming Hong, Hideki Goto, Mark Fesler, Boone Goodgame, Zhiming Li, Adam Olszewski, Joan Ashby, Shen Yin, Wahib S. Ead, Martin Janousek, Song Pham, Connie L. Batlevi, Michael C. Wei, Won-Seog Kim

Blood (2025) 146 (Supplement 1): 5509.

https://doi.org/10.1182/blood-2025-5509

Published: 2025

Journal Articles

Novel triplet combination of orelabrutinib, lenalidomide, and rituximab as frontlinetherapy for mantle cell lymphoma: Final results of polaris multicenter phase II study

Xiaohui Wang, Zheng Song, Xianhuo Wang, Huilai Zhang

Blood (2025) 146 (Supplement 1): 1803.

https://doi.org/10.1182/blood-2025-1803

Published: 2025

Journal Articles

Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma in Chinese population: A single-arm, multicenter, phase 2 trial

Blood (2025) 146 (Supplement 1): 1796.

https://doi.org/10.1182/blood-2025-1796

Published: 2025

Journal Articles

Single-cell analysis and functional profiling reveal galectin-3–driven reprogramming of the tumor immune microenvironment in transformed follicular lymphoma

Xiaohui Wang, Xianhuo Wang, Huilai Zhang

Blood (2025) 146 (Supplement 1): 5033.

https://doi.org/10.1182/blood-2025-5033

Published: 2025

Journal Articles

Glofitamab plus gemcitabine and oxaliplatin (GemOx) vs rituximab (R)-GemOx in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): Efficacy and safety in patient subgroups

Haifaa Abdulhaq, William Townsend, Matthew Ku, Gareth P. Gregory, Jeremy Abramson, Huiqiang Huang, Huilai Zhang, Dok Hyun Yoon, Won-Seog Kim, Herve Ghesquieres, Mark Hertzberg, Qing-Yuan Zhang, Murali Kesavan, Estefania Mulvihill, Martine Joanna Kallemeijn, Richard Ta, Voleak Choeurng, Linda Lundberg, Christopher Fox

Blood (2025) 146 (Supplement 1): 3743.

https://doi.org/10.1182/blood-2025-3743

Published: 2025

Journal Articles

ZAP trial: MRD-guided chemotherapy and maintenance de-escalation with zanubrutinib-g-CHOP in high-risk FL (Phase II)

Zhao Peiqi, Lanfang Li, Zhengzi Qian, Wei Li, Shiyong Zhou, Lihua Qiu, Xianming Liu, Huilai Zhang

Blood (2025) 146 (Supplement 1): 5380.

https://doi.org/10.1182/blood-2025-5380

Published: 2025

Journal Articles

First evaluation of novel cmoep (Liposomal Mitoxantrone-Based Chemotherapy) in front-line peripheral T-cell lymphoma: The compass Phase II study

Jingwei Yu, Jiesong Wang, Hongwei Xue, Zhengzi Qian, Lihua Qiu, Jin Zhang, Yan Huang, Lintao Bi, Lanfang Li, Huilai Zhang

Blood (2025) 146 (Supplement 1): 3647.

https://doi.org/10.1182/blood-2025-3647

Published: 2025

Journal Articles

A phase 1 study of lucar-G39D: A novel anti-CD20/CD19 dual-CAR allogeneic gamma delta T cells in adults with relapsed / refractory B-cell non-Hodgkin lymphoma (NHL)

Blood (2025) 146 (Supplement 1): 266.

https://doi.org/10.1182/blood-2025-266

Published: 2025

Journal Articles

Safety and effectiveness of brentuximab vedotin in patients with CD30- positive B-cell lymphoma: A multicenter, prospective, observational, real-world BRAVE study in China

Jia Li, Wei Zhang, Huaqing Wang, Weili Zhao, Chuanxu Liu, Kaiyang Ding, Wenyang Huang, Zengjun Li, Xiaobo Wang, Hongmei Jing, Zheng Ge, Jianli Wang, Ziheng Guo, Huilai Zhang, Ou Bai

Blood (2025) 146 (Supplement 1): 5466.

https://doi.org/10.1182/blood-2025-5466

Published: 2025

Journal Articles

Effectiveness and safety of polatuzumab vedotin combined with zuberitamab plus cyclophosphamide, doxorubicin and prednisone in untreated diffuse large B-cell lymphoma: A real-world study from China

Wei Li, Lanfang Li, Xianming Liu, Zhao Peiqi, Zhengzi Qian, Lihua Qiu, Shiyong Zhou, Huilai Zhang

Blood (2025) 146 (Supplement 1): 2747.

https://doi.org/10.1182/blood-2025-2747

Published: 2025

Journal Articles

Effectiveness of polatuzumab-based regimens among elderly patients with previously untreated diffuse large B-cell lymphoma: A systematic review and meta-analysis

Zhao Peiqi, Yunyue Ju, Yukun Lan, Huilai Zhang

Blood (2025) 146 (Supplement 1): 8098.

https://doi.org/10.1182/blood-2025-8098

Published: 2025

Journal Articles

Trium study: Exploring MRD-guided triplet therapy with sonrotoclax, zanubrutinib, and CD20mab in Untreated Mantle Cell Lymphoma: A prospective, multicenter, Phase II Study

Peiqi Zhao, Yulan Zhou, Lihua Qiu, Yinan Gao, Zhengzi Qian, Xingli Zou, Pan Zhao, Jianxia He, Fei Li, Huilai Zhang

Blood (2025) 146 (Supplement 1): 1809.

https://doi.org/10.1182/blood-2025-1809

Published: 2025

Journal Articles

Single-cell atlas of circulating immunity identifies shared specific DLBCL signatures predicting response to R-CHOP and CD19 CAR-t therapies

Sicong Zhang, Xiangrui Meng, Jiayi Han, Xianhuo Wang, Huilai Zhang

Blood (2025) 146 (Supplement 1): 3556.

https://doi.org/10.1182/blood-2025-3556

Published: 2025

Journal Articles

PIM1 mutation drives ANXA2 membrane relocalization and promotes lymphomagenesis through PI3K/AKT/mTOR pathway in DLBCL

Ning Zhang, Yaxiao Lu, Cong Sun, Xianhuo Wang, Huilai Zhang

Blood (2025) 146 (Supplement 1): 3257.

https://doi.org/10.1182/blood-2025-3257

Published: 2025

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Safety and effectiveness of brentuximab vedotin in Chinese adult patients with classical Hodgkin's lymphoma: Results from a multicenter, prospective, observational, real-world study

Clinical activity and immune correlates of glofitamab combined with tislelizumab in relapsed/refractory follicular lymphoma: A translational study

Final analysis of the randomized phase 2 ROSEWOOD study of zanubrutinib + obinutuzumab vs obinutuzumab monotherapy in patients with relapsed/refractory follicular lymphoma

Proteolysis-targeting chimera (PROTAC) targeting bruton tyrosine kinase (BTK) degradation for cancer therapy in mantle cell lymphoma

Frontline brentuximab vedotin and PD-1 inhibitors in elderly Chinese Hodgkin lymphoma: Real-world survival benefits validated by geriatric and biomarker correlates

Sustained clinical benefit of glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab plus GemOx (R-GemOx) in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): 3-year follow-up of STARGLO

Novel triplet combination of orelabrutinib, lenalidomide, and rituximab as frontlinetherapy for mantle cell lymphoma: Final results of polaris multicenter phase II study

Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma in Chinese population: A single-arm, multicenter, phase 2 trial

Single-cell analysis and functional profiling reveal galectin-3–driven reprogramming of the tumor immune microenvironment in transformed follicular lymphoma

Glofitamab plus gemcitabine and oxaliplatin (GemOx) vs rituximab (R)-GemOx in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): Efficacy and safety in patient subgroups

ZAP trial: MRD-guided chemotherapy and maintenance de-escalation with zanubrutinib-g-CHOP in high-risk FL (Phase II)

First evaluation of novel cmoep (Liposomal Mitoxantrone-Based Chemotherapy) in front-line peripheral T-cell lymphoma: The compass Phase II study

A phase 1 study of lucar-G39D: A novel anti-CD20/CD19 dual-CAR allogeneic gamma delta T cells in adults with relapsed / refractory B-cell non-Hodgkin lymphoma (NHL)

Safety and effectiveness of brentuximab vedotin in patients with CD30- positive B-cell lymphoma: A multicenter, prospective, observational, real-world BRAVE study in China

Effectiveness and safety of polatuzumab vedotin combined with zuberitamab plus cyclophosphamide, doxorubicin and prednisone in untreated diffuse large B-cell lymphoma: A real-world study from China

Effectiveness of polatuzumab-based regimens among elderly patients with previously untreated diffuse large B-cell lymphoma: A systematic review and meta-analysis

Trium study: Exploring MRD-guided triplet therapy with sonrotoclax, zanubrutinib, and CD20mab in Untreated Mantle Cell Lymphoma: A prospective, multicenter, Phase II Study

Single-cell atlas of circulating immunity identifies shared specific DLBCL signatures predicting response to R-CHOP and CD19 CAR-t therapies

PIM1 mutation drives ANXA2 membrane relocalization and promotes lymphomagenesis through PI3K/AKT/mTOR pathway in DLBCL

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only